Driver mutations in the EGFR, BRAF, and KRAS genes represent a combined ~60% of all genomic variants driving oncogenesis of many solid tumor diseases, especially lung cancer. SeraCare is expanding its liquid biopsy portfolio with the addition of low-plex (single-gene) reference materials for clinically-validated biomarkers in these genes as ground truth standards for molecular testing of circulating tumor DNA patient samples by PCR or NGS technologies. These products are designed for validation and standardization of clinical biomarkers in CLIA and CAP-accredited laboratory developed tests (LDTs).
The Seraseq ctDNA EGFR Panel Mutation Mix product has an allele frequency of 0.1%.
Size distribution similar to native cfDNA
Offered as a purified DNA mixture for ease of use during processing
Mutation precisely quantitated with digital PCR
Single well-characterized GM24385 human genomic DNA as background wild-type material
Manufactured in GMP-compliant and ISO 13485-certified facilities